-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Taysha Gene Therapies, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2019 to Q4 2024.
- Taysha Gene Therapies, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$19.9M, a 22.7% decline year-over-year.
- Taysha Gene Therapies, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$91.5M, a 26.3% decline year-over-year.
- Taysha Gene Therapies, Inc. annual Operating Income (Loss) for 2024 was -$91.5M, a 26.3% decline from 2023.
- Taysha Gene Therapies, Inc. annual Operating Income (Loss) for 2023 was -$72.4M, a 55.4% increase from 2022.
- Taysha Gene Therapies, Inc. annual Operating Income (Loss) for 2022 was -$162M, a 6.25% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)